65,437 trials
Norovirus · Healthy Participants
Primary: Number of Participants With Serum Samples Obtained on Day 8 for Assessment of Seropositivity for Both Anti-NoV GI.1 VLP and GII.4 VLP Antibodies — 48 participants
Rheumatoid Arthritis
Primary: Number of Participants Assigned Tocilizumab Monotherapy Versus Tocilizumab as Part of Combination Therapy at Study Inclusion — 228; 349 participants — p=0.0230
Neuroblastoma · Medulloblastoma · Relapse
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 14 participants
Basal Cell Carcinoma of the Skin · Recurrent Skin Cancer
Primary: Percent Change in Biomarker (GLI2 Protein) Levels — 75 percentage decrease
Glaucoma
Primary: Presence of Retinal Vascular Dysregulation (RVD) — 7; 4 Participants
Cancer
Primary: Change of Pain Intensity From Baseline(visit1) to 4weeks.(visit3) — 1.586; 1.559 units on a scale
Glaucoma
Primary: Presence of Retinal Blood Flow Autoregulation — 14 participants — p=<0.0001
Heart Failure
Primary: Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) — 33; 36 participants
Schizophrenia
Primary: Number of Subjects With Treatment-emergent Adverse Events (TEAEs) — 51; 190 participants
Psoriasis, Arthritic
Primary: Percentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response at Week 24 (Efficacy of Ixekizumab in Participants With Active Psoriatic…
Arthritis, Rheumatoid
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAE) — 56; 58 participants
Obesity · Overweight · Body Weight
Primary: Mean Change From Baseline in Body Weight at Week 12 — -0.51; -0.92 Kilogram — p=0.187
Psychosis Prodrome
Primary: Conversion to Psychosis — 1; 2 participants
Obsessive-Compulsive Disorder
Primary: Number of Patients Who Met and Exceeded Response Criteria of Yale-Brown Obsessive-Compulsive Scale — 5 participants
Lung Cancer
Primary: Primary Tumor Control at 2 Years — 96.2 percentage of patients